Research in Dr. Liu's molecular neuroscience program in CAMH has focused on identification of novel biomarkers as well as novel targets for the development of protein peptide or small molecule therapeutics for the treatment of psychiatric diseases. Her research has led to a number of highly novel and internationally-recognized discoveries (e.g. Liu et al., Nature 2000; Lee et al., Cell 2002; Pei et al., Nature Medicine 2010; Su et al., Neuron 2014; Li et al.., Journal of Clinical Investigation 2020) that are being translated into potential novel therapeutics for treating neuropsychiatric disease such as depression, schizophrenia and PTSD.